Cecilie Johannessen Landmark

  • MScPharm, PhD, Senior researcher
 

Publications 2019

Henning O, Johannessen Landmark C, Nakken KO, Lossius MI (2019)
Nonadherence to treatment regimens in epilepsy from the patient's perspective and predisposing factors: Differences between intentional and unintentional lack of adherence
Epilepsia, 60 (5), e58-e62
DOI 10.1111/epi.14734, PubMed 30980675

Johannessen Landmark C, Fløgstad I, Baftiu A, Syvertsen M, Enger U, Koht J, Johannessen SI (2019)
Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy
Epilepsy Res, 155, 106148 (in press)
DOI 10.1016/j.eplepsyres.2019.05.016, PubMed 31195184

Larsen Burns M, Kinge E, Stokke Opdal M, Johannessen SI, Johannessen Landmark C (2019)
Therapeutic drug monitoring of gabapentin in various indications
Acta Neurol Scand, 139 (5), 446-454
DOI 10.1111/ane.13075, PubMed 30710348

Larsen Burns M, Nikanorova M, Baftiu A, Borg Rasmussen J, Johannessen SI, Johannessen Landmark C (2019)
Pharmacokinetic Variability and Clinical Use of Lacosamide in Children and Adolescents in Denmark and Norway
Ther Drug Monit, 41 (3), 340-347
DOI 10.1097/FTD.0000000000000599, PubMed 30688870

Publications 2018

Johannessen Landmark C, Farmen AH, Burns ML, Baftiu A, Lossius MI, Johannessen SI, Tomson T (2018)
Pharmacokinetic variability of valproate during pregnancy - Implications for the use of therapeutic drug monitoring
Epilepsy Res, 141, 31-37
DOI 10.1016/j.eplepsyres.2018.02.004, PubMed 29453075

Reimers A, Berg JA, Burns ML, Brodtkorb E, Johannessen SI, Johannessen Landmark C (2018)
Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines
Drug Des Devel Ther, 12, 271-280
DOI 10.2147/DDDT.S154388, PubMed 29467570

Publications 2017

Johannessen Landmark C, Burns ML, Baftiu A, Farmen AH, Lossius MI, Johannessen SI, Tomson T (2017)
Pharmacokinetic variability of valproate in women of childbearing age
Epilepsia, 58 (10), e142-e146
DOI 10.1111/epi.13872, PubMed 28833045

Reimers A, Berg JA, Burns ML, Landmark CJ (2017)
Harmonised reference ranges for antiepileptic drugs
Tidsskr Nor Laegeforen, 137 (12-13), 864-865
DOI 10.4045/tidsskr.17.0392, PubMed 28655236

Svendsen T, Brodtkorb E, Baftiu A, Burns ML, Johannessen SI, Johannessen Landmark C (2017)
Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability
Neurochem Res, 42 (7), 2077-2083
DOI 10.1007/s11064-017-2234-8, PubMed 28349359

Publications 2016

Baftiu A, Johannessen Landmark C, Rusten IR, Feet SA, Johannessen SI, Larsson PG (2016)
Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications
Eur J Clin Pharmacol, 72 (10), 1245-1254
DOI 10.1007/s00228-016-2092-3, PubMed 27411937

Halvorsen KH, Johannessen Landmark C, Granas AG (2016)
Prevalence of Different Combinations of Antiepileptic Drugs and CNS Drugs in Elderly Home Care Service and Nursing Home Patients in Norway
Epilepsy Res Treat, 2016, 5153093
DOI 10.1155/2016/5153093, PubMed 27525114

Johannessen Landmark C, Henning O, Johannessen SI (2016)
Proconvulsant effects of antidepressants - What is the current evidence?
Epilepsy Behav, 61, 287-291
DOI 10.1016/j.yebeh.2016.01.029, PubMed 26926001

Johannessen Landmark C, Svendsen T, Dinarevic J, Kufaas RF, Reimers A, Brodtkorb E, Baftiu A, Burns ML, Johannessen SI (2016)
The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice
Ther Drug Monit, 38 (4), 499-505
DOI 10.1097/FTD.0000000000000306, PubMed 27414974

Mevaag M, Henning O, Baftiu A, Granas AG, Johannessen SI, Nakken KO, Johannessen Landmark C (2016)
Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs
Acta Neurol Scand, 135 (1), 80-87
DOI 10.1111/ane.12578, PubMed 26923477

Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, Johannessen Landmark C (2016)
Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome
Epilepsy Res, 129, 125-131
DOI 10.1016/j.eplepsyres.2016.12.001, PubMed 28043062

Publications 2015

Baftiu A, Johannessen Landmark C, Nikaj V, Neslein IL, Johannessen SI, Perucca E (2015)
Availability of antiepileptic drugs across Europe
Epilepsia, 56 (12), e191-7
DOI 10.1111/epi.13210, PubMed 26477534

Beiske GA, Holmøy T, Beiske AG, Johannessen SI, Johannessen Landmark C (2015)
Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis
Mult Scler Int, 2015, 317859
DOI 10.1155/2015/317859, PubMed 26221541

Johannessen Landmark C, Beiske G, Baftiu A, Burns ML, Johannessen SI (2015)
Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice
Seizure, 28, 88-91
DOI 10.1016/j.seizure.2015.02.017, PubMed 25758302

Johannessen Landmark C, I Johannessen S (2015)
Pharmacotherapy in epilepsy - does gender affect safety?
Expert Opin Drug Saf, 15 (1), 1-4
DOI 10.1517/14740338.2016.1117606, PubMed 26650146

Publications 2013

Karouni M, Henning O, Larsson PG, Johannessen SI, Johannessen Landmark C (2013)
Pharmacological treatment of psychiatric comorbidity in patients with refractory epilepsy
Epilepsy Behav, 29 (1), 77-81
DOI 10.1016/j.yebeh.2013.06.031, PubMed 23939032

Korczyn AD, Schachter SC, Brodie MJ, Dalal SS, Engel J, Guekht A, Hecimovic H, Jerbi K, Kanner AM, Johannessen Landmark C, Mares P, Marusic P, Meletti S, Mula M, Patsalos PN, Reuber M, Ryvlin P, Štillová K, Tuchman R, Rektor I (2013)
Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)
Epilepsy Behav, 28 (2), 283-302
DOI 10.1016/j.yebeh.2013.03.012, PubMed 23764496

Publications 2012

Johannessen Landmark C, Baftiu A, Tysse I, Valsø B, Larsson PG, Rytter E, Johannessen SI (2012)
Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication
Ther Drug Monit, 34 (4), 440-5
DOI 10.1097/FTD.0b013e31825ee389, PubMed 22777154

Johannessen Landmark C, Patsalos PN (2012)
Methodologies used to identify and characterize interactions among antiepileptic drugs
Expert Rev Clin Pharmacol, 5 (3), 281-92
DOI 10.1586/ecp.12.10, PubMed 22697591

Publications 2011

Johannessen Landmark C, Johannessen SI, Tomson T (2011)
Host factors affecting antiepileptic drug delivery-pharmacokinetic variability
Adv Drug Deliv Rev, 64 (10), 896-910
DOI 10.1016/j.addr.2011.10.003, PubMed 22063021

Publications 2010

Johannessen Landmark C, Patsalos PN (2010)
Drug interactions involving the new second- and third-generation antiepileptic drugs
Expert Rev Neurother, 10 (1), 119-40
DOI 10.1586/ern.09.136, PubMed 20021326

Publications 2009

Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI (2009)
Antiepileptic drugs in epilepsy and other disorders--a population-based study of prescriptions
Epilepsy Res, 87 (1), 31-9
DOI 10.1016/j.eplepsyres.2009.07.005, PubMed 19679449

Publications 2008

Johannessen Landmark C (2008)
Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy
CNS Drugs, 22 (1), 27-47
DOI 10.2165/00023210-200822010-00003, PubMed 18072813

Johannessen Landmark C, Johannessen SI (2008)
Pharmacological management of epilepsy: recent advances and future prospects
Drugs, 68 (14), 1925-39
DOI 10.2165/00003495-200868140-00001, PubMed 18778117

Page visits: 2168